Eimskipafelag Islands hf.
The Nomination Committee is a sub-committee of the Board of Directors which shall assist the Board with the process of Board succession planning, identification and nomination of Board candidates, alternate Board candidates as well as members of the Board‘s committees.
Eimskip‘s Annual General Meeting will be held on 25 March 2021 and the Nomination Committee is now open for nominations.
Declaration of candidacy shall be submitted to the committee on a special form that can be accessed at the Company‘s website www.eimskip.com/agm2021 and shall be returned to the email nominationcommittee@eimskip.com
Deadline for declaring candidacy to the Nomination Committee passes at 16:00 (GMT) on Monday 22 February 2021. The committee reserves the right to discuss candidacies that are received later.
The committee‘s proposal of nomination of Board candidates will be published two weeks before the Annual General Meeting, along with the proposals of the Board, on 11 March.
General deadline for declaring candidacy to the Board of Directors passes 10 days before the Annual General Meeting, or at 16:00 (GMT) on 15 March 2021. The activities of the Nomination Committee do not limit candidates’ rights to declare their candidacy to the Board of Directors until that point in time.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
FLSmidth A/S9.7.2025 07:30:53 CEST | Press release
Transactions under share buy-back programme
Fingerprint Cards AB8.7.2025 22:20:54 CEST | Press release
Postponement of Reverse Share Split in Fingerprint Cards AB (publ) due to technical reasons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom